Latest Conference Articles

December 11th 2014, 2:29pm

San Antonio Breast Cancer Symposium

The addition of bevacizumab (Avastin) to standard neoadjuvant chemotherapy significantly improved pathologic complete response (pCR) rates in women with basal-like breast cancer compared with non-basal-like subtypes.

December 11th 2014, 12:30pm

San Antonio Breast Cancer Symposium

December 11th 2014, 8:33am

San Antonio Breast Cancer Symposium

Nab-paclitaxel (Abraxane) proved markedly more effective than conventional paclitaxel as part of a neoadjuvant regimen for patients with high-risk early breast cancer in a large German study presented at the 2014 San Antonio Breast Cancer Symposium.

December 10th 2014, 3:33pm

San Antonio Breast Cancer Symposium

December 10th 2014, 3:24pm

San Antonio Breast Cancer Symposium

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the potential for immune checkpoint blockage as treatment for patients with advanced breast cancer.

December 10th 2014, 12:54pm

San Antonio Breast Cancer Symposium

The PD-1 inhibitor pembrolizumab has demonstrated promising clinical activity with an acceptable safety profile in heavily pretreated patients with recurrent metastatic triple-negative breast cancer.

December 10th 2014, 12:45pm

San Antonio Breast Cancer Symposium

The addition of the investigational PI3K inhibitor pictilisib to fulvestrant in patients with metastatic breast cancer yielded some intriguing findings in the phase II FERGI study.

December 10th 2014, 12:11pm

San Antonio Breast Cancer Symposium

Among HER2-positive breast cancer patients treated with chemotherapy alone, women with high levels of stromal tumor-infiltrating lymphocytes had an 80% lower likelihood of disease recurrence compared to those with lower TIL counts.

December 9th 2014, 5:34pm

ASH Annual Meeting and Exposition

Some patients with heavily treated acute myelogenous leukemia benefited from treatment with the BCL-2 inhibitor venetoclax (ABT-199).

December 9th 2014, 5:07pm

ASH Annual Meeting and Exposition

Ninety-six percent of patients with relapsed or refractory Hodgkin lymphoma who received treatment with the combination of brentuximab vedotin and bendamustine responded to treatment without experiencing dose-limiting toxicity.

December 9th 2014, 3:37pm

ASH Annual Meeting and Exposition

Almost 90% of patients with relapsed or refractory mantle cell lymphoma responded to the targeted combination of ibrutinib and rituximab.

December 9th 2014, 1:54pm

ASH Annual Meeting and Exposition

Ian Flinn, MD, PhD, director of the hematologic malignancies program at Sarah Cannon Research Institute, discusses findings from a phase I study that explored monotherapy with the PI3K-gamma and delta inhibitor duvelisib (IPI-145) in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

December 9th 2014, 6:10am

ASH Annual Meeting and Exposition

Jia Ruan, MD, PhD, is an associate professor at Weill Cornell Medical College, discusses sustained remissions experienced by patients treated with the combination of lenalidomide and rituximab as initial treatment for MCL.

December 8th 2014, 5:39pm

ASH Annual Meeting and Exposition

Patients with HIV-associated lymphoma can effectively be treated with autologous hematopoietic stem cell transplantation, with outcomes that are similar to patients without HIV.

December 8th 2014, 1:57pm

ASH Annual Meeting and Exposition

Noopur Raje, MD, from the Multiple Myeloma Program at Massachusetts General Hospital, discusses the unprecedented efficacy seen with monoclonal antibodies as treatments for patients with multiple myeloma.

December 8th 2014, 12:53pm

ASH Annual Meeting and Exposition

Treatment with elotuzumab in combination with lenalidomide and dexamethasone demonstrated encouraging efficacy in patients with relapsed/refractory multiple myeloma.

December 8th 2014, 6:32am

ASH Annual Meeting and Exposition

Treatment with nilotinib in combination with chemotherapy elicited complete hematological remissions in 87% of elderly patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.

December 8th 2014, 6:09am

ASH Annual Meeting and Exposition

The novel drug AG-221 generated durable remissions in patients with AML by targeting a mutation of the IDH2 gene in a small, first-in-man study that represents a new, chemotherapy-free approach for attacking the malignancy.

December 7th 2014, 5:06pm

ASH Annual Meeting and Exposition

The anti-CD19 chimeric antigen receptor-modified T-cell therapy CTL019 demonstrated an impressive 92% complete response rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

December 7th 2014, 4:37pm

ASH Annual Meeting and Exposition

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center in Houston, describes results from the phase III VALOR trial that explored vosaroxin plus cytarabine versus placebo and cytarabine in patients with first relapsed or refractory acute myeloid leukemia.